CN100500644C - Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use - Google Patents
Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use Download PDFInfo
- Publication number
- CN100500644C CN100500644C CNB2004100298017A CN200410029801A CN100500644C CN 100500644 C CN100500644 C CN 100500644C CN B2004100298017 A CNB2004100298017 A CN B2004100298017A CN 200410029801 A CN200410029801 A CN 200410029801A CN 100500644 C CN100500644 C CN 100500644C
- Authority
- CN
- China
- Prior art keywords
- synthesis
- gabapentin
- pregabalin
- yield
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 229960002870 gabapentin Drugs 0.000 title claims abstract description 69
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 46
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 239000002243 precursor Substances 0.000 title abstract description 3
- 208000004296 neuralgia Diseases 0.000 claims abstract description 19
- 206010015037 epilepsy Diseases 0.000 claims abstract description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 7
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 82
- 230000015572 biosynthetic process Effects 0.000 description 82
- 238000003786 synthesis reaction Methods 0.000 description 81
- 238000000034 method Methods 0.000 description 55
- -1 III Chemical compound 0.000 description 44
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 42
- 230000009471 action Effects 0.000 description 34
- 238000009833 condensation Methods 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 22
- 238000010511 deprotection reaction Methods 0.000 description 20
- 238000000921 elemental analysis Methods 0.000 description 20
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 11
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 10
- 229940035437 1,3-propanediol Drugs 0.000 description 10
- 150000005690 diesters Chemical class 0.000 description 10
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 10
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 229940093476 ethylene glycol Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940083957 1,2-butanediol Drugs 0.000 description 6
- 229940043375 1,5-pentanediol Drugs 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 5
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 5
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003556 anti-epileptic effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000003951 lactams Chemical class 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000034308 Grand mal convulsion Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003063 anti-neuropathic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000031264 Nerve root compression Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010068268 Tumour compression Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- ZKVJJVAZTBDPNW-UHFFFAOYSA-N ctk1d8407 Chemical compound NNNNN ZKVJJVAZTBDPNW-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- OASOQJKCZXXDMI-UHFFFAOYSA-N ethane-1,2-diol;hydrochloride Chemical compound Cl.OCCO OASOQJKCZXXDMI-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the interconnected medicine precursor of gabapentin and pregabalin and its non-toxic pharmaceutically acceptable salt and their use in preparing medicines for treating epilepsy, neurogenic pain and/or anxiety neurosis.
Description
Technical Field
The present invention relates to mutual prodrugs of Gabapentin (Gabapentin) and Pregabalin (Pregabalin), non-toxic pharmaceutically acceptable salts thereof and their use in the preparation of medicaments for the treatment of epilepsy, neuropathic pain, and/or anxiety.
Technical Field
Neuropathic pain is a serious disease seriously threatening human life and health, and the incidence rate is up to 1%. Neuropathic pain refers to pain caused by damage or pathological changes of the nervous system, including intractable pain due to tumor compression, polyneuritis pain in diabetic patients, trigeminal neuralgia, herpes zoster neuralgia, and pain caused by spinal cord or nerve root compression in spinal disease patients. Neuropathic pain is often long-term and chronic, lasting days or months, as opposed to acute pain due to tissue damage. Persistent pain seriously affects the quality of life of people. The clinical causes of neuropathic pain are wide, the symptoms are various, the pathological mechanism is complex, and the conventional analgesics such as opioid potent narcotic analgesics and non-steroidal anti-inflammatory drugs have no obvious curative effect on the neuropathic pain, so the neuropathic pain becomes one of the difficulties of clinical treatment.
The treatment of epilepsy is also a problem to be solved in medicine today. The incidence of active epilepsy is about 0.7% of the general population, and the population is 400 tens of thousands of patients worldwide. Similar to neuropathic pain, the pathogenesis of epilepsy is also complex.
Although research into therapeutic drugs for neuropathic pain and epilepsy has made significant progress, research to find new compounds is slow due to the complex pathological mechanisms of both, which may involve various receptors, pathways and neurotransmitters, and difficulty in mechanism-based drug design; however, the existing medicines have limited curative effect, and no single medicine can completely eliminate any pain symptom.
Gabapentin (Gabapentin, shown in formula I) and Pregabalin (Pregabalin, shown in formula II) are effective drugs for treating neuropathic pain and epilepsy, but because of large polarity, the Gabapentin and Pregabalin are difficult to pass through a blood brain barrier, large-dose administration is required, and large-dose administration generates large toxic and side effects, such as dizziness, somnolence, nystagmus, sedation and the like, so that the tolerance of a patient is influenced; moreover, the medicine needs to be taken 3-4 times a day because of the short effective time in the body and the inconvenient taking.
In addition, lactam impurities are easily formed during the preparation and storage of I and II. Acids, bases or certain excipients may accelerate the formation of lactam by-products, resulting in uncontrollable drug quality.
Disclosure of Invention
The invention discovers that molecules of gabapentin and pregabalin both contain free amido and carboxyl, and the molecules are converted into a precursor form of amide or ester, so that lipophilicity can be increased, penetrability to blood brain barrier is increased, distribution in brain tissue is improved, dosage is reduced, and side effect is avoided; but also can prolong the action time.
Therefore, the mutual prodrug formed between gabapentin and pregabalin and the non-toxic pharmaceutically acceptable salt thereof have better activity of resisting epilepsy and treating neuropathic pain, the biological half-life period is obviously prolonged, and the lactam byproduct is not generated after long-term storage.
Accordingly, a first aspect of the invention provides a mutual prodrug of formula III:
wherein,
X is O or NH, n-1-6, R3Is straight-chain or branched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms.
In another aspect, the invention relates to a pharmaceutical composition comprising a mutual prodrug of formula III or a non-toxic pharmaceutically acceptable salt or pharmaceutically acceptable salt thereof as an active ingredient in combination with a pharmaceutically acceptable excipient.
The invention also relates to the use of a compound of formula III for the preparation of a medicament for the treatment of neuropathic pain and epilepsy.
According to the invention, the mutual prodrugs of the invention are compounds represented by formula III.
According to the invention, pharmaceutically acceptable salts of compounds of formula III include salts with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid, or organic acids such as: formic acid, acetic acid, methanesulfonic acid, benzoic acid, tartaric acid, maleic acid or fumaric acid; examples of the alkali metal include lithium, sodium or potassium, and examples of the alkaline earth metal include calcium and magnesium; examples of the inorganic base include sodium hydroxide, potassium hydroxide and aqueous ammonia; examples of organic bases are methylamine, ethylamine, triethylamine or dimethylethylamine.
According to the present invention, the pharmaceutical composition of the present invention can be used in the form of an oral or parenteral dosage form, such as a tablet, a capsule or an injection.
The compound III of the present invention can be prepared by the following synthetic route:
wherein,
X is O or NH, n-1-6, R3Is straight-chain or branched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms.
In the above reaction route, gabapentin or pregabalin is used as a raw material, and tert-Butyloxycarbonyl (BOC) is used for protecting amino to obtain IV; IV reacts with diol under the action of DCC at room temperature or low temperature to obtain monoester V; condensing V and BOC protected gabapentin or pregabalin under the action of DCC to generate protected diester VI; VI, removing the protecting group by hydrochloric acid to obtain the target compound III.
Detailed Description
The present invention can be more specifically explained by the following examples. However, the scope of the present invention is not limited to the following examples.
EXAMPLE 1 tert-Butoxycarbonyl (BOC) protected gabapentin (IV)1) Synthesis of (2)
0.80g (0.02mol) of NaOH was added to a 250ml eggplant-shaped bottle, 20ml of water was added to dissolve the solution, the mixture was cooled in an ice bath and stirred magnetically, 3.42g (0.02mol) of gabapentin was further added, and after the solid was completely dissolved, a solution of 5.24g (0.024m0l) of BOC anhydride in 30ml of dioxane and a solution of 0.88g of NaOH in 30ml of water were alternately added to keep the pH of the reaction solution at about 9 and the reaction solution was added over about 30 minutes. After the addition was completed, the reaction was carried out in ice bath for 2 hours and then at room temperature for 2 hours. The reaction was complete. Extracting excess BOC anhydride with diethyl ether for 30ml × 5 times, discarding diethyl ether layer, adding 5% citric acid into water layer under stirring to pH3, separating solid, adding 80ml ethyl acetate to extract precipitate for 80ml × 3 times, mixing organic phases, washing ethyl acetate layer with water for 30ml × 2 times, and saturating NaClWashing with 30ml of water, 3 times, anhydrous MgSO4Drying for 4-6 hours. Then filtering out the drying agent, evaporating the solvent to obtain III14.7g of white solid, yield 86.72%, mp: 129-130 ℃,1H-NMR(CDCl3,400MHz,δ ppm):1.45(s,9H,-C(CH3)3) 1.2-1.55(d, 10H), 2.32(s, 2H), 3.17(d, 2H), 5.0(s, 1H, CO-NH-), 11.5(s, 1H, -COOH); TLC: petroleum ether as developing agent EtAc CH3OH(5:2:0.5),Rf=0.34。
Example 2 Tert-Butoxycarbonyl (BOC) protected Pregabalin (IV)2) Synthesis of (2)
With reference to the procedure of example 1, pregabalin was reacted with BOC anhydride to obtain III as a white solid2Yield 90.73%, mp: 70-71 ℃; MS (ESI, m/e): 258.4(M-1), 260.3(M +1), 282.3(M + Na);
TLC: petroleum ether as developing agent EtAc CH3OH(5:2:0.5),Rf=0.34。
EXAMPLE 3 Synthesis of t-butyloxycarbonyl-protected gabapentin ethylene glycol Mono ester (V)1) Synthesis of (2)
Adding IV into 100ml eggplant-shaped bottle12.5g (0.00922mol), anhydrous CH2Cl220ml of the solution was stirred magnetically in an ice bath to dissolve the solid, and a solution of 3.43g (0.00922 mol. times.6) of ethylene glycol in 5ml of anhydrous DMF was added. After cooling to 0 ℃ DCC1.99g (0.00922 mol. times.1.05) was dissolved in 5ml of anhydrous CH dropwise2Cl2After reacting in ice bath for 1 hour, 0.25g of DMAP was added, and then the ice bath was removed and the reaction was carried out at room temperature for 12 hours. After the reaction, the precipitated DCU was filtered off, the solvent was distilled off under reduced pressure, EtAc100ml was added for dissolution, the precipitated DCU was filtered off again, and the EtAc layer was separately washed with 5% NaHCO3Wash 30ml X3 times, 5% citric acid wash 25ml X2 times, 5% NaHCO3Washing 30ml × 3 times, washing 30ml × 3 times with saturated NaCl, adding anhydrous MgSO4Drying for 4-6 hours. Then, the drying agent was filtered off, and the solvent was distilled off to obtain 3.0g of a colorless viscous liquid. Passing through a silica gel column, eluting: petroleum ether EtAc CH3OH 5:2:0.5 to obtain V12.8g, yield: 96.2 percent; TLC: petroleum ether as developing agent EtAc CH3OH(5:2:0.5),Rf=0.59;MS(ESI,m/e):316.2(M+1)。
Example 4 Synthesis of t-butyloxycarbonyl-protected pregabalin ethylene glycol Mono-ester (V)2) Synthesis of (2)
Method according to example 3, IV2Condensation with ethylene glycol under the action of DCC to obtain V2The yield is as follows: 95.4 percent of the total weight of the mixture,
TLC: petroleum ether as developing agent EtAc CH3OH(5:2:0.5),Rf=0.57;MS(ESI,m/e):326(M+Na)。
EXAMPLE 5 Synthesis of 1, 3-propanediol gabapentin monoester protected with tert-butyloxycarbonyl group (V)3) Synthesis of (2)
Method according to example 3, IV1Condensation with 1, 3-propanediol under the action of DCC to obtain V3The yield is as follows: 97.5 percent.
EXAMPLE 6 Synthesis of 1, 4-butanediol gabapentin monoester protected with tert-butyloxycarbonyl group (V)4) Synthesis of (2)
Method according to example 3, IV1Condensing with 1, 4-butanediol under the action of DCC to obtain V4The yield is as follows: 97.8 percent.
EXAMPLE 7 Synthesis of tert-Butoxycarbonyl protected gabapentin 1, 5-pentanediol monoester (V)5) Synthesis of (2)
Method according to example 3, IV1Condensation with 1, 5-pentanediol under the action of DCC to obtain V5The yield is as follows: 93.8 percent.
EXAMPLE 8 Synthesis of tert-Butoxycarbonyl protected gabapentin 1, 6-hexanediol monoester (V)6) Synthesis of (2)
Method according to example 3, IV1Condensation with 1, 6-hexanediol under the action of DCC to give V6The yield is as follows: 93.4 percent.
EXAMPLE 9 Synthesis of 1, 3-propanediol monoester of pregabalin protected with tert-butyloxycarbonyl group (V)7) Synthesis of (2)
Method according to example 3, IV2Condensation with 1, 3-propanediol under the action of DCC to obtain V7The yield is as follows: 96.7 percent.
EXAMPLE 10 Synthesis of 1, 4-butanediol monoester of pregabalin protected by t-butyloxycarbonyl (V)8) Synthesis of (2)
Method according to example 3, IV2Condensing with 1, 4-butanediol under the action of DCC to obtain V8The yield is as follows: 94.1 percent.
EXAMPLE 11 Synthesis of 1, 2-propanediol gabapentin monoester protected with tert-butyloxycarbonyl group (V)9) Synthesis of (2)
Method according to example 3, IV1Condensation with 1, 2-propanediol under the action of DCC to obtain V9The yield is as follows: 96.5 percent.
EXAMPLE 12 Synthesis of 1, 2-butanediol gabapentin monoester protected with tert-butyloxycarbonyl group (V)10) Synthesis of (2)
Method according to example 3, IV1Condensation with 1, 2-butanediol under the action of DCC to obtain V10The yield is as follows: 95.9 percent.
EXAMPLE 13 Synthesis of 1, 3-butanediol gabapentin monoester protected with tert-Butoxycarbonyl group (V)11) Synthesis of (2)
Method according to example 3, IV1Condensation with 1, 3-butanediol under the action of DCC to obtain V11The yield is as follows: 96.4 percent.
EXAMPLE 14 Synthesis of t-butyloxycarbonyl-protected gabapentin neopentyl glycol monoester (V)12) Synthesis of (2)
Method according to example 3, IV1Condensation with neopentyl glycol under the action of DCC to give V12The yield is as follows: 91.4 percent.
EXAMPLE 15 Synthesis of t-butyloxycarbonyl-protected gabapentin ethylene glycol diester (VI)1) Synthesis of (2)
Adding V into 100ml eggplant-shaped bottle11.7g (0.00553mol), anhydrous CH2Cl220ml, ice bath, electromagnetic stirring and then adding IV11.5g (0.00553 mol). After cooling to 0 ℃ DCC1.20g (0.00553 mol. times.1.05) was added dropwise to the solution, which was dissolved in 5ml of anhydrous CH2Cl2After reacting in ice bath for 1 hour, 0.1g of DMAP was added, and then the ice bath was removed and the reaction was carried out at room temperature for 12 hours. After the reaction was completed, precipitated DCU was filtered off, the solvent was distilled off under reduced pressure, EtAc100ml was added for dissolution, precipitated DCU was filtered off again, and EtAc layers were each separated with 5% NaHCO3Wash 30ml X3 times, 5% citric acid wash 25ml X2 times, 5% NaHCO3Washing 30ml × 3 times, washing 30ml × 3 times with saturated NaCl, adding anhydrous MgSO4Drying for 4-6 hours. Then, the drying agent was filtered off, and the solvent was distilled off to obtain 3.0g of a colorless viscous liquid. Passing through silica gel column, and adding petroleum ether EtAc CH3Eluting with mixed solvent of OH 5:1.5:0.5 to obtain VI12.7 g. Yield: 88.2 percent; TLC: petroleum ether as developing agent EtAc CH3OH(5:1.5:0.5),Rf=0.65;MS(ESI,m/e):569.4(M+1)。
EXAMPLE 16 Synthesis of t-butyloxycarbonyl-protected pregabalin ethylene glycol diester (VI)2) Synthesis of (2)
Method according to example 15, V2Condensation with IV2 under the action of DCC to give VI2The yield is as follows: 91.3 percent;
TLC: petroleum ether as developing agent EtAc CH3OH(5:1.5:0.5),Rf=0.66;MS(ESI,m/e):545.5(M+1),567.5(M+Na)。
EXAMPLE 17 Synthesis of t-butyloxycarbonyl-protected gabapentin/pregabalin ethyleneglycol heterodiester (VI)3) Synthesis of (2)
Method according to example 15, V1Under the action of DCC, with IV2Condensation to give VI3The yield is as follows: the mass ratio of the mixture to the mixed solution is 87.6 percent,
TLC: petroleum ether as developing agent EtAc CH3OH(5:1.5:0.5),Rf=0.65;MS(ESI,m/e):557.2。
EXAMPLE 18 Synthesis of 1, 3-propanediol gabapentin protected by tert-Butoxycarbonyl group (VI)4) Synthesis of (2)
Method according to example 15, V3Under the action of DCC, with IV1Condensation to give VI4The yield is as follows: 93.7 percent.
EXAMPLE 19 Synthesis of tert-Butoxycarbonyl protected gabapentin 1, 4-butanediol diester (VI)5) Synthesis of (2)
Method according to example 15, V4Under the action of DCC, with IV1Condensation to give VI5The yield is as follows: 94.3 percent.
EXAMPLE 20 Synthesis of tert-Butoxycarbonyl protected gabapentin 1, 5-pentanediol diester (VI)6) Synthesis of (2)
Method according to example 15, V4Under the action of DCC, with IV1Condensation to give VI6The yield is as follows: 92.3 percent.
EXAMPLE 21 Synthesis of tert-Butoxycarbonyl-protected gabapentin 1, 6-hexanediol diester (VI)7) Synthesis of (2)
Method according to example 24, V5Under the action of DCC, with IV1Condensation to give VI7The yield is as follows: 90.9 percent.
EXAMPLE 22 Boc-protected gabapentin/pregabalin 1, 3-propanediol heterodiester (VI)8) Synthesis of (2)
Method according to example 15, V3Under the action of DCC, with IV2Condensation to give VI7The yield is as follows: 88.7 percent.
EXAMPLE 23 Boc-protected gabapentin/pregabalin 1, 4-butanediol Heterodiester (VI)9) Synthesis of (2)
Method according to example 15, V4Under the action of DCC, with IV2Condensation to give VI9The yield is as follows: 86.8 percent.
EXAMPLE 24 Boc-protected gabapentin/pregabalin 1, 5-pentanediol heterodiester (VI)10) Synthesis of (2)
Method according to example 15, V5Under the action of DCC, with IV2Condensation to give VI10The yield is as follows: 86.8 percent.
EXAMPLE 25 Boc-protected gabapentin/pregabalin 1, 6-hexanediol heterodiester (VI)11) Synthesis of (2)
Method according to example 15, V6Under the action of DCC, with IV2Condensation to give VI11The yield is as follows: 83.4 percent.
EXAMPLE 26 tert-Butoxycarbonyl protected pregabalin 1, 3-propanediol diester (VI)12) Synthesis of (2)
Method according to example 15, V7Under the action of DCC, with IV2Condensation to give VI11The yield is as follows: 92.5 percent.
EXAMPLE 27 Boc-protected pregabalin 1, 4-butanediol diester (VI)13) Synthesis of (2)
Method according to example 15, V8Under the action of DCC, with IV2Condensation to give VI13The yield is as follows: 92.5 percent.
EXAMPLE 28 Boc-protected gabapentin 1, 2-propanediol diester (VI)14) Synthesis of (2)
Method according to example 24, V9Under the action of DCC, with IV1Condensation to give VI14The yield is as follows: 93.9 percent.
Example 29 t-butyloxycarbonyl protected gabapentin 1,2-butanediol diester (VI)15) Synthesis of (2)
Method according to example 15, V10Under the action of DCC, with IV1Condensation to give VI15The yield is as follows: 91.4 percent.
EXAMPLE 30 tert-Butoxycarbonyl protected gabapentin 1, 3-butanediol diester (VI)16) Synthesis of (2)
Method according to example 15, V11Under the action of DCC, with IV1Condensation to give VI16The yield is as follows: 92.1 percent.
EXAMPLE 31 tert-Butoxycarbonyl protected gabapentin neopentyl glycol diester (VI)17) Synthesis of (2)
Method according to example 15, V12Under the action of DCC, with IV1Condensation to give VI17The yield is as follows: 93.1 percent.
EXAMPLE 32 Boc-protected gabapentin/pregabalin 1, 2-propanediol heterodiester (VI)18) Synthesis of (2)
Method according to example 15, V9Under the action of DCC, with IV2Condensation to give VI18The yield is as follows: 84.3 percent.
EXAMPLE 33 Boc-protected gabapentin/pregabalin 1, 2-butanediol Heterodiester (VI)19) Synthesis of (2)
Method according to example 15, V10Under the action of DCC, with IV2Condensation to give VI19The yield is as follows: 83.8 percent.
Example 34 tert-Butoxycarbonyl protected gabapentin/pregabalin 1, 3-butanediol Heterodiester (VI)20) Synthesis of (2)
Method according to example 15, V11Under the action of DCC, with IV2Condensation to give VI20The yield is as follows: 81.3 percent.
Example 35Boc protected gabapentin/pregabalin neopentyl glycol heterodiester (VI)21) Synthesis of (2)
Method according to example 15, V12Under the action of DCC, with IV2Condensation to give VI21The yield is as follows: 83.5 percent.
EXAMPLE 36 Synthesis of gabapentin/gabapentin ethylene glycol hydrochloride (III)1) Synthesis of (2)
VI is mixed with1The reaction mixture was dissolved in 20ml of anhydrous EtAc with stirring, and 20ml of 4N HCl/EtAc solution was added thereto, followed by stirring at room temperature. White solid began to precipitate after 15min of reaction, and the reaction was continued for 1 hour and stopped. The precipitate was filtered off, washed with cold EtAc and dry ether, respectively, and dried in vacuo. To obtain III11.75g, mp: 176-178 ℃, yield: 100 percent; elemental analysis (C)20H38N2O4Cl2): calculated values: 54.42% of C, 8.62% of H and 6.35% of N; experimental values: c54.01%, H9.05%, N6.04%;1H-NMR(CD3OD,600MHz,δ ppm):1.41-1.56(d,20H),2.57(s,4H),3.07(s,4H),4.34(s,4H);MS(ESI,m/e):368.9(M+1)。
example 37 Synthesis of Pregabalin/Pregabalin ethylene glycol diacetate hydrochloride (III)2) Synthesis of (2)
Method according to example 36, VI2Deprotection with hydrochloric acid to give III2mp: 154-155 ℃, yield: 100 percent; elemental analysis (C)18H38N2O4Cl2): calculated values: c51.80%, H9.11%, N6.71%; experimental values: c51.35%, H9.26%, N6.65%;1H-NMR(CD3OD,600MHz,δ ppm):0.92-0.95(dd,12H,J=6.6Hz),1.27(m,4H),1.66(m,2H),2.24(m,2H),2.48(d,4H),2.98(m,4H),4.33(s,4H);MS(m/e):345.2(M+1)。
example 38 gabapentin/pregabalin ethylene glycol Heterodiester hydrochloride (III)3) Synthesis of
Method according to example 36, VI3Deprotection with hydrochloric acid to give III3Mp: 101-103 ℃, yield: 100 percent; elemental analysis (C)19H38N2O4Cl2): calculated values: c53.14%, H8.86%, N6.53%; experimental values: 53.22% of C, 8.83% of H and 6.44% of N;1H-NMR(CD3OD,600MHz,δ ppm):0.92-0.95(dd,12H,J=6.6Hz),1.27(m,4H),1.41-1.56(d,10H),1.66(m,2H),2.24(m,2H),2.48(d,4H),2.57(s,4H),2.98(m,4H),3.07(s,4H),4.33(s,4H);MS(ESI,m/e):357.4(M+1)。
EXAMPLE 39 Synthesis of gabapentin/gabapentin 1, 3-propanediol diester hydrochloride (III)4) Synthesis of (2)
Method according to example 36, VI4Deprotection with hydrochloric acid to give III4The yield is as follows: 100%, mp: 179-181 ℃ and elemental analysis (C)21H40N2O4Cl2): calculated values: c55.38%, H8.79%, N6.15%; experimental values: c55.05%, H8.88%, N6.06%;1H-NMR(CD3OD,600MHz,δ ppm):1.46-1.59(m,20H),2.00(m,2H),2.67(s,4H),3.09(s,4H),4.27(t,4H),8.33(s,6H,-NH 2 HCl)。
EXAMPLE 40 Synthesis of gabapentin/gabapentin 1, 4-butanediol diester hydrochloride (III)5) Synthesis of (2)
Method according to example 36, VI5Deprotection with hydrochloric acid to give III5The yield is as follows: 100%, mp: 171-173 ℃ and element analysis (C)22H42N2O4Cl2): calculated values: c56.29%, H8.95%, N5.97%; experimental values: 56.50% of C, 8.83% of H and 5.82% of N;1H-NMR(CD3OD,600MHz,δ ppm):1.44-1.56(d,20H),2.65(s,4H),3.02(s,4H),4.15(s,4H),8.44(s,6H,-NH 2 HCl)。
EXAMPLE 41 Synthesis of gabapentin/gabapentin 1, 5-pentanediol diester hydrochloride (III)6) Synthesis of (2)
Method according to example 36, VI6Deprotection with hydrochloric acid to give III6The yield is as follows: 100%, mp: 177 to 179 ℃; elemental analysis (C)23H44N2O4Cl2): calculated values: c57.14%, H9.11%, N5.80%; experimental values: c57.08%, H9.17%, N6.68%;1H-NMR(CD3OD,400MHz,δ ppm):1.38-1.72(m,26H),2.62(s,4H),3.09(s,4H),4.15(t,4H),8.42(s,6H,-NH 2 HCl)%。
EXAMPLE 42 Synthesis of gabapentin/gabapentin 1, 6-hexanediol diester hydrochloride (III)7) Synthesis of (2)
Method according to example 36, VI7Deprotection with hydrochloric acid to give III7The yield is as follows: 100%, mp: 177 to 179 ℃; elemental analysis (C)24H46N2O4Cl2): calculated values: c57.95%, H9.25%, N5.63%; experimental values: c57.80%, H9.29%, N5.49%;1H-NMR(CD3OD,400MHz,δ ppm):1.37-1.69(m,28H),2.59(s,4H),3.09(s,4H),4.11(t,4H),8.41(s,6H,-NH 2 HCl)。
example 43 gabapentin/pregabalin 1, 3-propanediol heterodiester hydrochloride (III)8) Synthesis of (2)
Method according to example 36, VI8Deprotection with hydrochloric acid to give III7Yield: 100%, mp: 116-118 ℃; elemental analysis (C)20H40N2O4Cl2): calculated values: c54.17%, H9.03%, N6.32%; experimental values: 54.15% of C, 9.03% of H and 6.39% of N;1H-NMR(CD3OD,600MHz,δ ppm):0.90-0.93(t,6H),1.22-1.65(m,13H),1.99(t,2H),2.56(s,1H),2.56-2.65(m,4H),3.12-3.13(m,4H),4.24(t,4H),8.30(s,6H,-NH 2 HCl)。
example 44 gabapentin/pregabalin 1, 4-butanediol Heterodiester hydrochloride (III)9) Synthesis of (2)
Method according to example 36, VI9Deprotection with hydrochloric acid to give III9The yield is as follows: 100%, mp: 105-107 ℃; elemental analysis (C)21H42N2O4Cl2): calculated values: c55.14%, H9.19%, N6.12%; experimental values: 54.99% of C, 9.40% of H and 6.18% of N;1H-NMR(CD3OD,600MHz,δ ppm):0.91-0.93(d,6H),1.21-1.77(m,17H),2.35-2.67(m,5H),3.06(s,4H),4.15(s,4H),8.36-8.49(d,6H,-NH 2 HCl)。
example 45 gabapentin/pregabalin 1, 5-pentanediol heterodiester hydrochloride (III)10) Synthesis of (2)
Method according to example 36, VI10Deprotection with hydrochloric acid to give III10The yield is as follows: 100%, mp: 109-111 ℃; elemental analysis (C)22H44N2O4Cl2): calculated values: c56.06%, H9.34%, N5.94%; experimental values: 56.09% of C, 9.69% of H and 6.14% of N;1H-NMR(CD3OD,400MHz,δ ppm):0.91-0.93(d,6H),1.19-1.78(m,19H),2.33(m,1H),2.55-2.61(m,4H),3.05-3.12(d,4H),4.15(s,4H),8.34-8.48(d,6H,-NH 2 HCl)。
example 46 gabapentin/pregabalin 1, 6-hexanediol heterodiester hydrochloride (III)11) Synthesis of (2)
Method according to example 36, VI11Deprotection with hydrochloric acid to give III11The yield is as follows: 100%, mp: 88-90 ℃; elemental analysis (C)23H46N2O4Cl2): calculated values: 56.91% of C, 9.48% of H and 5.77% of N; experimental values: c56.90%, H9.63%, N5.87%;1H-NMR(CD3OD,400MHz,δ ppm):0.91-0.93(d,6H),1.18-1.68(m,21H),2.35(m,1H),2.53-2.58(d,4H),3.05-3.12(d,4H),4.12(s,4H),8.34-8.50(d,6H,-NH 2 HCl)。
example 47 Pregabalin/Pregabalin 1, 3-propanediol diester hydrochloride (III)12) Synthesis of (2)
Method according to example 36, VI12Deprotection with hydrochloric acid to give III12The yield is as follows: 100%, mp: 132-134 ℃; elemental analysis (C)19H40N2O4Cl2): calculated values: c52.90%, H9.28%, N6.50%; experimental values: c52.90%, H9.54%, N6.28%;1H-NMR(CD3OD,400MHz,δ ppm):0.91-0.94(m,12H),1.20-1.37(m,4H),1.66(m,2H),2.01(s,2H),2.39(s,2H),2.56(m,4H),3.05(d,4H),4.23(m,4H),8.31(s,6H,-NH 2 HCl)。
example 48 Pregabalin/Pregabalin 1, 4-butanediol diester hydrochloride (III)13) Synthesis of (2)
Method according to example 36, VI13Deprotection with hydrochloric acid to give III13The yield is as follows: 100%, mp: 114-116 ℃; elemental analysis (C)20H42N2O4Cl2): calculated values: 53.93% of C, 9.44% of H and 6.29% of N; experimental values: c53.40%, H9.48%, N6.22%;1H-NMR(CD3OD,400MHz,δ ppm):0.91-0.94(t,12H),1.20-1.37(m,4H),1.66(m,2H),2.05(s,2H),2.36(s,2H),2.51-2.62(d,4H),3.05(d,4H),4.20(d,4H),8.38(s,6H,-NH 2 HCl)。
example 49 gabapentin/gabapentin 1, 2-propanediol bisEster hydrochloride (III)14) Synthesis of (2)
Method according to example 36, VI14Deprotection with hydrochloric acid to give III14The yield is as follows: 100%, mp: 128-130 ℃; elemental analysis (C)20H38N2O4Cl2): calculated values: c55.38%, H8.79%, N6.15%; experimental values: c55.40%, H8.79%, N6.33%;1H-NMR(CD3OD,400MHz,δ ppm):1.19-1.64(m,23H),2.66-2.98(m,4H),3.00-3.17(m,4H),4.12-4.30(d,2H),5.21-5.24(m,1H),8.37(s,6H,-NH 2 HCl)。
example 50 gabapentin/gabapentin 1, 2-butanediol diester hydrochloride (III)15) Synthesis of (2)
Method according to example 36, VI15Deprotection with hydrochloric acid to give III15The yield is as follows: 100%, mp: 92-95 ℃; elemental analysis (C)22H42N2O4Cl2): calculated values: c56.29%, H8.95%, N5.97%; experimental values: 55.77% of C, 9.29% of H and 5.97% of N;1H-NMR(CD3OD,400MHz,δ ppm):0.91-0.95(t,3H),1.19-1.67(m,22H),2.61-2.88(m,4H),3.03-3.21(m,4H),4.07-4.33(d,2H),5.05-5.10(m,1H),8.34(s,6H,-NH 2 HCl)。
example 51 gabapentin/gabapentin 1, 3-butanediol diester hydrochloride (III)16) Synthesis of (2)
Method according to example 36, VI16Deprotection with hydrochloric acid to give III16Yield: 100%, mp: 176-178 ℃; elemental analysis (C)22H42N2O4Cl2): calculated values: c56.29%, H8.95%, N5.97%; experimental values: 55.99% of C, 9.03% of H and 6.04% of N;1H-NMR(CD3OD,400MHz,δ ppm):1.19-1.57(m,23H),1.88-1.97(m,2H),2.57-2.75(m,4H),3.03-3.26(m,4H),4.13-4.28(d,2H),5.08-5.09(m,1H),8.30(s,6H,-NH 2 HCl)。
example 52 gabapentin/gabapentin neopentyl glycol diester hydrochloride (III)17) Synthesis of (2)
Method according to example 36, VI17Deprotection with hydrochloric acid to give III17The yield is as follows: 100%, mp: 138-140 ℃; elemental analysis (C)23H44N2O4Cl2): calculated values: c57.14%, H9.11%, N5.80%; experimental values: c57.35%, H9.56%, N5.79%;1H-NMR(CD3OD,400MHz,δ ppm):0.94s,6H),1.35-1.60(m,20H),2.67(s,4H),3.11(s,4H),3.97(s,4H),8.33(s,6H,-NH 2 HCl)。
example 53 gabapentin/pregabalin 1, 2-propanediol heterodiester hydrochloride (III)18) Synthesis of (2)
Method according to example 36, VI18Deprotection with hydrochloric acid to give III18The yield is as follows: 100%, mp: 87-89 ℃; elemental analysis (C)20H40N2O4Cl2): calculated values: c54.17%, H9.03%, N6.32%; experimental values: 53.76% of C, 9.02% of H and 6.27% of N;1H-NMR(CD3OD,400MHz,δ ppm):0.91-0.93(d,6H),1.19-1.65(m,16H),2.38-3.19(m,9H),3.96-4.40(d,2H),5.18-5.23(m,1H),8.30(s,6H,-NH 2 HCl)。
example 54 gabapentin/pregabalin 1, 2-butanediol Heterodiester hydrochloride (III)19) Synthesis of (2)
Method according to example 36, VI19Deprotection with hydrochloric acid to give III19The yield is as follows: 100%, mp: 88-90 ℃; elemental analysis (C)21H42N2O4Cl2): calculated values: c55.14%, H9.19%, N6.12%; experimental values: c55.01%,H 9.15%,N 6.31%;1H-NMR(CD3OD,600MHz,δ ppm):0.91-0.96(s,9H),1.19-1.68(m,12H),2.08(s,1H),2.35-3.20(m,8H),4.06-4.10(d,1H),4.37-4.49(d,1H),5.01-5.05(m,1H),8.29-8.40(d,6H,-NH 2 HCl)。
Example 55 gabapentin/pregabalin 1, 3-butanediol Heterodiester hydrochloride (III)20) Synthesis of (2)
Method according to example 36, VI20Deprotection with hydrochloric acid to give III20The yield is as follows: 100%, mp: 86-88 ℃; elemental analysis (C)21H42N2O4Cl2): calculated values: c55.14%, H9.19%, N6.12%; experimental values: 55.56% of C, 9.06% of H and 6.56% of N;1H-NMR(CD3OD,600MHz,δ ppm):0.86-0.93(s,6H),1.17-1.68(m,18H),1.90-1.95(m,1H),2.39-2.68(m,4H),3.02-3.17(m,4H),4.11-4.39(d,1H),5.04-5.07(m,1H),8.26-8.38(d,6H,-NH 2 HCl)。
example 56 gabapentin/pregabalin neopentyl glycol heterodiester hydrochloride (III)21) Synthesis of (2)
Method according to example 36, VI21Deprotection with hydrochloric acid to give III21The yield is as follows: 100%, mp: 148-150 ℃; elemental analysis (C)22H44N2O4Cl2): calculated values: c56.06%, H9.34%, N5.94%; experimental values: c56.04%, H9.61%, N5.94%;1H-NMR(CD3OD,600MHz,δ ppm):0.90-0.98(m,12H),1.01-1.67(m,13H),2.50(s,1H),2.53-2.75(m,4H),3.02-3.16(m,4H),3.90-3.99(m,4H),8.29(s,6H,-NH 2 HCl)。
biological activity assay
The compounds of interest were subjected to preliminary evaluation of anti-neuropathic pain activity and anti-epileptic activity.
1. Anti-neuropathic pain Activity
Pharmacodynamic evaluation of the target compounds against neuropathic pain was performed using a model of chronic compressive neuralgia of the sciatic nerve (CCI). The method comprises the following steps:
SD rats, male, weighing 160-. Separating sciatic nerve from peripheral tissue with sterile glass hook, loosely tying 4 rings with sterile chromium catgut (No. 4, diameter 0.15mm), spacing 1-2mm between each ring, locally scattering penicillin powder, suturing muscle tissue and skin, and placing in cage with cork dust. The sham group exposed only the sciatic nerve, and the other treatments were as above.
Rats of different days after surgery were placed in a metal cage and their soles were stimulated with different gram weights of cellosilk, 5 seconds apart for each stimulation, until a cellosilk was found that caused 4 to 6 rat foot-lifting reactions out of 10, and their gram weights were recorded and set as a threshold (unit: g). And simultaneously recording the times of raising the feet of the animals when the cellosilk with different gram weights is stimulated for 10 times, and setting the highest threshold value to be 26 g.
The compound was administered intraperitoneally (60mg/kg) 1 hour prior to the experiment, 5-6 animals per group, and the effect of the drug on pain threshold after administration was observed. The threshold statistics adopts nonparametric Test WilcoVon2-Sample Test and Kruskal-Wallis Test; data analysis was performed using SASS data processing software.
Maximum analgesic percentage (%) - (threshold after drug treatment-threshold before drug treatment)/(threshold maximum analgesic value-threshold before drug treatment) ×%.
The results are shown in Table 1.
TABLE 1 Experimental observations of hypersensitivity to pain of rat CCI model
2. Anti-epileptic activity
The anti-epileptic effect of the target compounds was evaluated using a mouse maximal electroshock seizure model and a mouse pentaazane convulsive Model (MET). The former is a well-known experimental model of epileptic grand mal, and the latter is an experimental animal model for observing the curative effect of the anti-epileptic grand mal.
2.1 mouse maximal electroshock attack Model (MES)
Kunming mice, 20 +/-2 mg in body weight, male and female, are divided into groups randomly, and each group comprises 10 animals. Firstly, immersing the dentate clamp electrodes in physiological saline, respectively clamping the dentate clamp electrodes on two ears of a mouse, then introducing currents (mA) with different intensities, and taking MES as MES of the mouse which generates hindlimb rigid extension and flexion and then twins, thereby determining that the current intensity of MES generated by more than 97 percent of mice is 8.02 mA.
On the basis of the above experiment, different doses of samples to be tested are given at p.o 0.5h before the experiment, normal saline is used as a control to observe the MES resistance, and the Bless method is adopted to calculate the anti-startling effect ED50The value is obtained. In addition, 90% of the effective dose is administered, the anti-MES effect is observed at different intervals, and the 50% effective time t is determined1/2. The results are shown in Table 2.
TABLE 2 anti-maximal electroshock onset effect in mice
2.2 mouse model of convulsion due to Penetracycline (MET)
Kunming mice, 20 +/-2 mg in body weight, male and female, are divided into groups randomly, and each group comprises 10 animals. Injecting pentylenetetrazol sc, and determining the dose value of pentylenetetrazol of more than 97% of animals producing convulsion as 92.1mg kg-1 with twinning convulsion of animals lasting for more than 3 seconds within 30min as final index.
On the basis of the above experiment, different doses of samples to be tested are given at p.o 0.5h before the experiment, normal saline is used as a control to observe the anti-MET effect and the anti-MES effect, and the Bless method is adopted to calculate the anti-fright effect ED50The value is obtained. In addition, 90% of the effective dose is administered, the anti-MES effect is observed at different intervals, and the 50% effective time t is determined1/2. The results are shown in Table 3.
TABLE 3 anticonvulsant action against pentaerythrine in mice
Claims (3)
2. A pharmaceutical composition comprising a compound of formula III according to claim 1 as an active ingredient, and a pharmaceutically acceptable excipient.
3. Use of the mutual prodrug of claim 1 for the manufacture of a medicament for the treatment of neuropathic pain or epilepsy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100298017A CN100500644C (en) | 2004-03-25 | 2004-03-25 | Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100298017A CN100500644C (en) | 2004-03-25 | 2004-03-25 | Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1673212A CN1673212A (en) | 2005-09-28 |
CN100500644C true CN100500644C (en) | 2009-06-17 |
Family
ID=35046017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100298017A Expired - Fee Related CN100500644C (en) | 2004-03-25 | 2004-03-25 | Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100500644C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813924B (en) * | 2012-05-17 | 2014-06-18 | 高同强 | Drug combination product for analgesia based on sinomenine |
CN113582927B (en) * | 2020-04-30 | 2023-07-04 | 苏州恩华生物医药科技有限公司 | Celecoxib and pregabalin co-amorphous substance and preparation method thereof |
-
2004
- 2004-03-25 CN CNB2004100298017A patent/CN100500644C/en not_active Expired - Fee Related
Non-Patent Citations (6)
Title |
---|
加巴喷丁用于神经病理性疼痛治疗的研究进展. 刘国凯等.中国临床药理学与治疗学,第8卷第3期. 2003 |
加巴喷丁用于神经病理性疼痛治疗的研究进展. 刘国凯等.中国临床药理学与治疗学,第8卷第3期. 2003 * |
神经病理性疼痛治疗药物的研究进展. 史卫国等.国外医学药学分册,第30卷第5期. 2003 |
神经病理性疼痛治疗药物的研究进展. 史卫国等.国外医学药学分册,第30卷第5期. 2003 * |
神经病理性疼痛的治疗进展. 刘国凯等.中国麻醉学杂志,第23卷第2期. 2003 |
神经病理性疼痛的治疗进展. 刘国凯等.中国麻醉学杂志,第23卷第2期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1673212A (en) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2132327C1 (en) | Substituted carboxamides and pharmaceutical composition on said | |
WO2001049650A1 (en) | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | |
JPH05502023A (en) | N-(1-(2-carboxyethyl)cycloalkylcarbonyl)-beta-alanine derivative for pharmaceutical use | |
EP2399900B1 (en) | Geranyl compounds | |
TW200845981A (en) | Compounds and compositions as channel activating protease inhibitors | |
KR960012204B1 (en) | Beta-aminoethyl substituted phenyl compound and anti-inflammatory or analgesic compositions containing them | |
DE69405572T2 (en) | MATRIX METALLOPROTEASE INHIBITORS | |
EP0688314B1 (en) | Prodrug derivatives of enzyme inhibitors with hydroxyl groups, methods of preparing them and their use | |
US20120022147A1 (en) | 2, 6 xylidine derivatives for the treatment of pain | |
US20160317479A1 (en) | Method of treating or preventing pain | |
US6846843B2 (en) | β-thioamino acids | |
CN100500644C (en) | Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use | |
ES2476284T3 (en) | Compounds with both analgesic and antihyperalgesic efficacy | |
US20030229145A1 (en) | Pain treatment methods and compositions | |
CA1058186A (en) | L-pyroglutamyl-l-prolinamide | |
DE60010711T2 (en) | AMIDO SPIROPIPERIDINE PROMOTES THE RELEASE OF GROWTH HORMONES | |
US6784208B2 (en) | Method for preventing and treating visceral pain and gastrointestinal disorders | |
CN115745890A (en) | Ester bond compound, preparation method and application thereof, and analgesic | |
EP0187009B1 (en) | Compounds and compositions having anti-inflammatory and analgesic activity | |
WO2019119117A1 (en) | Glucosamine derivatives for the prevention or treatment of joint disorders | |
AU2019254962B9 (en) | Isoindole derivatives | |
Shi et al. | Design, Synthesis, and Preliminary Evaluation of Gabapentin‐Pregabalin Mutual Prodrugs in Relieving Neuropathic Pain | |
CN115894371B (en) | Sinomenine amide derivative, preparation method and application thereof, and analgesic drug | |
DE69015208T2 (en) | DERIVATIVES OF GLUTAMINE AND ASPARGINIC ACID WITH ANTIGASTRIN EFFECT AND METHOD FOR THE PRODUCTION THEREOF. | |
EP0309261B1 (en) | Butenoic acid amides, their salts, pharmaceutical compositions containing them and process for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 Termination date: 20160325 |
|
CF01 | Termination of patent right due to non-payment of annual fee |